Table 3 Univariate and multivariate... | American Society of Hematology

Table 3

Univariate and multivariate analysis for disease-free survival

Variable	Univariate			Multivariate
Variable	HR	95% CI	P	HR	95% CI	P
Age, y	1.01	0.98-1.04	.446
Sex	1.36	0.76-2.42	.304
Diagnosis*	—	—	.226
Cytogenetics (high risk vs others)	1.04	0.58-1.87	.888
Stage at transplantation*	—	—	.120
Donor type*	—	—	.648
CMV status*	—	—	.132
CD34⁺ cell count (10⁶/kg steps)	1.01	0.93-1.10	.797
Marrow infiltration (10% steps)	1.23	1.09-1.40	.001†	1.14	1.01-1.29	.033†
Peripheral blast count	1.02	1.01-1.03	.001†	1.01	0.99-1.03	.237
Chemotherapy cycles before transplantation	1.43	1.10-1.86	.008†	1.38	1.01-1.08	.043†
Angiopoietin-2 (ng/mL) (0.1 ng steps)	1.03	1.00-1.06	.034†
Angiopoietin-2 (greater vs less than median)	2.26	1.24-4.11	.008†	2.46	1.27-4.76	.005†

Variable	Univariate			Multivariate
Variable	HR	95% CI	P	HR	95% CI	P
Age, y	1.01	0.98-1.04	.446
Sex	1.36	0.76-2.42	.304
Diagnosis*	—	—	.226
Cytogenetics (high risk vs others)	1.04	0.58-1.87	.888
Stage at transplantation*	—	—	.120
Donor type*	—	—	.648
CMV status*	—	—	.132
CD34⁺ cell count (10⁶/kg steps)	1.01	0.93-1.10	.797
Marrow infiltration (10% steps)	1.23	1.09-1.40	.001†	1.14	1.01-1.29	.033†
Peripheral blast count	1.02	1.01-1.03	.001†	1.01	0.99-1.03	.237
Chemotherapy cycles before transplantation	1.43	1.10-1.86	.008†	1.38	1.01-1.08	.043†
Angiopoietin-2 (ng/mL) (0.1 ng steps)	1.03	1.00-1.06	.034†
Angiopoietin-2 (greater vs less than median)	2.26	1.24-4.11	.008†	2.46	1.27-4.76	.005†

HR indicates hazard ratio; CI, confidence interval; and —, not applicable.

HR and CI for categorical variables are only displayed in case of multivariate significance.

Circulating Ang-2 serum levels were significantly elevated in patients compared with healthy controls (P < .001).